BeyondSpring (BYSI) Research & Development (2016 - 2026)
BeyondSpring (BYSI) posted Research & Development of $1.1 million for Q1 2026, down 26.95% sequentially from $1.5 million in Q4 2025, and up 23.11% YoY from $874000.0 in Q1 2025.
BeyondSpring (BYSI) Research & Development (2016 - 2026) Analysis & Trends
BeyondSpring has reported Research & Development for 9 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Research & Development rose 23.11% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 64.1% YoY) and the FY2025 annual result came in at $4.4 million, up 65.96% from the prior year.
- Research & Development fell to $1.1 million in Q1 2026 per BYSI's latest filing, from $1.5 million in the prior quarter.
- Over five years, Research & Development peaked at $1.5 million in Q4 2025 and troughed at $472000.0 in Q4 2024.
- A 3-year average of $900888.9 and a median of $874000.0 in 2025 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 212.08% in 2025, down 20.87% in 2025.
- Over 3 years, Research & Development stood at $472000.0 in 2024, then surged by 212.08% to $1.5 million in 2025, then slipped by 26.95% to $1.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.1 million, $1.5 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | 973,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 973,000.00 |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 874,000.00 |
| Dec 31, 2024 | 472,000.00 |
| Sep 30, 2024 | 622,000.00 |
| Jun 30, 2024 | 829,000.00 |
| Mar 31, 2024 | 721,000.00 |
| Dec 31, 2021 | 5.79 Mn |
| Sep 30, 2021 | 8.46 Mn |
| Jun 30, 2021 | 11.33 Mn |
| Mar 31, 2021 | 11.31 Mn |
| Dec 31, 2020 | 8.42 Mn |
| Sep 30, 2020 | 8.64 Mn |
| Jun 30, 2020 | 11.03 Mn |
| Mar 31, 2020 | 13.70 Mn |
| Dec 31, 2019 | 12.58 Mn |
| Sep 30, 2019 | 7.23 Mn |